P2Y12
8 drugs Cardiovascular
7
approved indications
8
Approved Drugs
8
Companies
12
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 8 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Aurobindo Pharma 1 drug
AMNEAL 1 drug
AstraZeneca 1 drug
By Therapeutic Area
Cardiovascular 8 drugs
Drugs by Company PRO
Aurobindo Pharma 1 drug
AMNEAL 1 drug
AstraZeneca 1 drug
UNICHEM 1 drug
COSETTE 1 drug
Sanofi 1 drug
CHIESI 1 drug
GLAND 1 drug
By Therapeutic Area
Cardiovascular 8 drugs
PRASUGREL, TICAGRELOR, BRILINTA, PRASUGREL HYDROCHLORIDE +4 more
Indications Treated
Thrombotic Cardiovascular EventsAcute Coronary SyndromeUnstable AnginaNon-ST-Elevation Myocardial InfarctionST-Elevation Myocardial InfarctionMyocardial InfarctionStrokeStent ThrombosisCoronary Artery DiseaseAcute Ischemic StrokeTransient Ischemic AttackPeripheral Arterial Disease
All Drugs Targeting P2Y12
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| PRASUGREL Top | Aurobindo Pharma | 2017 | 7 | Cardiovascular |
| TICAGRELOR Top | AMNEAL | 2018 | 7 | Cardiovascular |
| BRILINTA Top | AstraZeneca | 2011 | 7 | Cardiovascular |
| PRASUGREL HYDROCHLORIDE | UNICHEM | 2023 | 5 | Cardiovascular |
| EFFIENT | COSETTE | 2009 | 5 | Cardiovascular |
| PLAVIX | Sanofi | 1997 | 5 | Cardiovascular |
| KENGREAL | CHIESI | 2015 | 2 | Cardiovascular |
| CANGRELOR | GLAND | 2025 | 2 | Cardiovascular |